Phase Ib Study to Evaluate the Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

• Status: Not yet recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd

Criteria

Inclusion Criteria:

• Have had a diagnosis of moderate to severe plaque psoriasis for at least 6 months prior to Baseline;

• Subjects with moderate to severe plaque psoriasis covering ≥10% BSA, with a PASI ≥12 and sPGA score ≥3 at Baseline;

• Able and willing to give written informed consent.

Exclusion Criteria:

• Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, etc.);

• Current drug-induced psoriasis, e.g., a new onset of psoriasis or an exacerbation of psoriasis induced by beta blockers, calcium channel blockers, antimalarial drugs or lithium;

• History or symptoms of malignancy in any organ system regardless of treatment, and regardless of evidence of recurrence or metastasis;

• Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject's participation in the study.